Last reviewed · How we verify
Chlor-Trimeton.
At a glance
| Generic name | Chlor-Trimeton. |
|---|---|
| Sponsor | Auburn University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Epistaxis
- Asthma
- Oropharyngeal pain
- Cough
- Nausea
- Pyrexia
- Sneezing
- Abdominal pain upper
- Vomiting
Key clinical trials
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer (PHASE2)
- Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection (PHASE2)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlor-Trimeton. CI brief — competitive landscape report
- Chlor-Trimeton. updates RSS · CI watch RSS
- Auburn University portfolio CI